Grant Goes to Elixiron Immunotherapeutics for Alzheimer’s Disease Treatment

According to an article from Newswire, the Alzheimer's Association is awarding Elixiron Immunotherapeutics one million dollars for work on their Alzheimer's treatment, EI1071. This money will go towards a clinical…

Continue Reading Grant Goes to Elixiron Immunotherapeutics for Alzheimer’s Disease Treatment
Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment
source: pixabay.com

Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment

The biotechnology company ContraFect has entered into an agreement with the Cystic Fibrosis Foundation. This funding agreement aims to investigate and develop direct lytic agents (DLAs) as a treatment for…

Continue Reading Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment
How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic
Source: pixabay.com

How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic

An Australian royal commission is investigating claims that children with disabilities are being excluded from online learning, according to The Guardian. They are also looking into issues with the services…

Continue Reading How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic

Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

A study conducted at the University of Texas has discovered that combination therapy may be a viable treatment for cholangiocarcinoma with BRAF mutations. Researchers treated participants with both dabrafenib and…

Continue Reading Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

Enrollment Begins in Trial of Duchenne Muscular Dystrophy Treatment

According to BioSpace, the first patient has been enrolled in a trial of pamrevlumab, a Duchenne muscular dystrophy treatment. The third phase of LELANTOS plans to evaluate the drug's effects…

Continue Reading Enrollment Begins in Trial of Duchenne Muscular Dystrophy Treatment
Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
source: pixabay.com

Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)

The HEALY ALS Platform Trial, being conducted by Biohaven Pharma, has begun enrolling patients. This study is intended to test the efficacy of three treatments on amyotrophic lateral sclerosis (ALS),…

Continue Reading Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
source: pixabay.com

ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results

CymaBay Therapeutics has recently released the results from ENHANCE, a study of seladelpar as a treatment for primary biliary cholangitis (PBC). These results were positive, proving that this medication has…

Continue Reading ICYMI: Study of Primary Biliary Cholangitis Treatment Shows Positive Results
Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Source: Pixabay

Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment

Alnylam Pharmaceuticals has submitted their clinical trial authorization (CTA) application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for their RNAi therapy, ALN-HSD, a treatment for nonalcoholic steatohepatitis (NASH).…

Continue Reading Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Close Menu